Evaluating the integration of genomics into cancer screening programmes: challenges and opportunities
Evaluating the integration of genomics into cancer screening programmes: challenges and opportunities
PURPOSE OF REVIEW: As the costs of genomic testing have fallen, and our understanding of genetic susceptibility to cancers has grown, there has been increasing interest in incorporating testing for cancer susceptibility genes, and polygenic risk estimates, into population cancer screening. A growing body of evidence suggests that this would be both clinically and cost-effective. In this article, we aim to explore the frameworks used to evaluate screening programmes, evaluate whether population screening for cancer susceptibility can be assessed using these standards, and consider additional issues and outcomes of importance in this context.
RECENT FINDINGS: There are tensions between traditional approaches of genetic testing (utilising tests with high sensitivity and specificity) and the principles of population screening (in which the screening test typically has low specificity), as well as the frameworks used to evaluate the two. Despite the existence of many screening guidelines, including consensus papers, these often do not align fully with broader considerations of genetic test evaluation. Population screening for genetic risk in cancer shifts the focus from diagnostics to prognostication and has wider implications for personal and familial health than existing screening programmes. In addition, understanding of the prevalence and penetrance of cancer susceptibility genes, required by many screening guidelines, may only be obtainable through population-level testing; prospective multi-disciplinary research alongside implementation will be essential.
SUMMARY: Appropriate evaluation of genetic screening for cancer risk will require modification of existing screening frameworks to incorporate additional complexity of outcomes and population values. As evidence supporting population screening for cancer susceptibility mounts, development of an appropriate evaluative framework, and expansion of public dialogue will be key to informing policy.
63-74
Briggs, Sarah
a86be0ed-f89b-4708-9390-570ed463585c
Slade, Ingrid
264e62f4-7c1e-4522-93f2-917de23e31d3
18 May 2019
Briggs, Sarah
a86be0ed-f89b-4708-9390-570ed463585c
Slade, Ingrid
264e62f4-7c1e-4522-93f2-917de23e31d3
Briggs, Sarah and Slade, Ingrid
(2019)
Evaluating the integration of genomics into cancer screening programmes: challenges and opportunities.
Current Genetic Medicine Reports, 7 (2), .
(doi:10.1007/s40142-019-00162-x).
Abstract
PURPOSE OF REVIEW: As the costs of genomic testing have fallen, and our understanding of genetic susceptibility to cancers has grown, there has been increasing interest in incorporating testing for cancer susceptibility genes, and polygenic risk estimates, into population cancer screening. A growing body of evidence suggests that this would be both clinically and cost-effective. In this article, we aim to explore the frameworks used to evaluate screening programmes, evaluate whether population screening for cancer susceptibility can be assessed using these standards, and consider additional issues and outcomes of importance in this context.
RECENT FINDINGS: There are tensions between traditional approaches of genetic testing (utilising tests with high sensitivity and specificity) and the principles of population screening (in which the screening test typically has low specificity), as well as the frameworks used to evaluate the two. Despite the existence of many screening guidelines, including consensus papers, these often do not align fully with broader considerations of genetic test evaluation. Population screening for genetic risk in cancer shifts the focus from diagnostics to prognostication and has wider implications for personal and familial health than existing screening programmes. In addition, understanding of the prevalence and penetrance of cancer susceptibility genes, required by many screening guidelines, may only be obtainable through population-level testing; prospective multi-disciplinary research alongside implementation will be essential.
SUMMARY: Appropriate evaluation of genetic screening for cancer risk will require modification of existing screening frameworks to incorporate additional complexity of outcomes and population values. As evidence supporting population screening for cancer susceptibility mounts, development of an appropriate evaluative framework, and expansion of public dialogue will be key to informing policy.
This record has no associated files available for download.
More information
Published date: 18 May 2019
Additional Information:
© The Author(s) 2019.
Identifiers
Local EPrints ID: 506545
URI: http://eprints.soton.ac.uk/id/eprint/506545
ISSN: 2167-4876
PURE UUID: a19662db-3747-4d03-9514-849370bc1dd0
Catalogue record
Date deposited: 11 Nov 2025 17:40
Last modified: 15 Nov 2025 03:21
Export record
Altmetrics
Contributors
Author:
Sarah Briggs
Author:
Ingrid Slade
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics